TY - JOUR
T1 - Detection rate of18 F-labeled PSMA PET/CT in biochemical recurrent prostate cancer
T2 - A systematic review and a meta-analysis
AU - Treglia, Giorgio
AU - Annunziata, Salvatore
AU - Pizzuto, Daniele A.
AU - Giovanella, Luca
AU - Prior, John O.
AU - Ceriani, Luca
PY - 2019/5
Y1 - 2019/5
N2 - Background: The use of radiolabeled prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) for biochemical recurrent prostate cancer (BRPCa) is increasing worldwide. Recently,18 F-labeled PSMA agents have become available. We performed a systematic review and meta-analysis regarding the detection rate (DR) of18 F-labeled PSMA PET/CT in BRPCa to provide evidence-based data in this setting. Methods: A comprehensive literature search of PubMed/MEDLINE, EMBASE, and Cochrane Library databases through 23 April 2019 was performed. Pooled DR was calculated on a per-patient basis, with pooled proportion and 95% confidence interval (95% CI). Furthermore, pooled DR of18 F-PSMA PET/CT using different cut-off values of prostate-specific antigen (PSA) was obtained. Results: Six articles (645 patients) were included in the meta-analysis. The pooled DR of18 F-labeled PSMA PET/CT in BRPCa was 81% (95% CI: 71–88%). The pooled DR was 86% for PSA ≥ 0.5 ng/mL (95% CI: 78–93%) and 49% for PSA < 0.5 ng/mL (95% CI: 23–74%). Statistical heterogeneity was found. Conclusions:18 F-labeled PSMA PET/CT demonstrated a good DR in BRPCa. DR of18 F-labeled PSMA PET/CT is related to PSA values with significant lower DR in patients with PSA < 0.5 ng/mL. Prospective multicentric trials are needed to confirm these findings.
AB - Background: The use of radiolabeled prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) for biochemical recurrent prostate cancer (BRPCa) is increasing worldwide. Recently,18 F-labeled PSMA agents have become available. We performed a systematic review and meta-analysis regarding the detection rate (DR) of18 F-labeled PSMA PET/CT in BRPCa to provide evidence-based data in this setting. Methods: A comprehensive literature search of PubMed/MEDLINE, EMBASE, and Cochrane Library databases through 23 April 2019 was performed. Pooled DR was calculated on a per-patient basis, with pooled proportion and 95% confidence interval (95% CI). Furthermore, pooled DR of18 F-PSMA PET/CT using different cut-off values of prostate-specific antigen (PSA) was obtained. Results: Six articles (645 patients) were included in the meta-analysis. The pooled DR of18 F-labeled PSMA PET/CT in BRPCa was 81% (95% CI: 71–88%). The pooled DR was 86% for PSA ≥ 0.5 ng/mL (95% CI: 78–93%) and 49% for PSA < 0.5 ng/mL (95% CI: 23–74%). Statistical heterogeneity was found. Conclusions:18 F-labeled PSMA PET/CT demonstrated a good DR in BRPCa. DR of18 F-labeled PSMA PET/CT is related to PSA values with significant lower DR in patients with PSA < 0.5 ng/mL. Prospective multicentric trials are needed to confirm these findings.
KW - DCFBC
KW - DCFPyL
KW - PET
KW - Prostate
KW - PSMA
KW - PSMA-1007
UR - http://www.scopus.com/inward/record.url?scp=85067106602&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85067106602&partnerID=8YFLogxK
U2 - 10.3390/cancers11050710
DO - 10.3390/cancers11050710
M3 - Review article
AN - SCOPUS:85067106602
VL - 11
JO - Cancers
JF - Cancers
SN - 2072-6694
IS - 5
ER -